United States - Patent - Alexion's Preliminary Injunction Motion Denied In Eculizumab BPCIA Litigation Against Samsung Bioepis mondaq.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mondaq.com Daily Mail and Mail on Sunday newspapers.
Basel: Sandoz has announced that the European Commission (EC) has granted marketing authorization for Pyzchiva (biosimilar ustekinumab) developed and registered by Samsung Bioepis. Pyzchiva is a key.
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Pyzchiva® approved as one of first ustekinumab biosimilars in EuropeEC approval based on robust development program.
Sandoz Confirms European Commission Approval of Pyzchiva® (ustekinumab), Further Strengthening Immunology Offering koreabizwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from koreabizwire.com Daily Mail and Mail on Sunday newspapers.
In this review, we discuss the most important recent developments in the biosimilars space, including new biosimilar approvals and launches, litigation under the Biologics Price.